Premium
Melanoma‐associated Antigen Synthesized In vitro for Active Specific Immunotherapy
Author(s) -
Hayashibe Kazuhito
Publication year - 1992
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.1992.tb03790.x
Subject(s) - melanoma , immunogen , antigen , immunotherapy , complementary dna , biology , monoclonal antibody , cdna library , immunogenicity , microbiology and biotechnology , immune system , antibody , immunology , cancer research , gene , biochemistry
The immunogenicity of the antigen molecule is a prerequisite for active specific immunotherapy for melanoma. Since most of the melanoma‐associated antigens recognized by the murine immune system are known to be not immunogenic in man, a detection and analysis system for melanoma‐associated antigens is required to reflect in vivo immune responses in patients with melanoma. One of the promising approaches, an attempt to develop human monoclonal antibodies from B lymphocytes of patients with melanoma, has met with limited success due to the difficulties of producing large amounts of antibodies and using them in immunochemical assays, because most of them belong to the IgM class and have low affinity. Our approach is to utilize the screening of a cDNA expression library constructed from mRNA extracted from cultured melanoma cells with antibodies from patients with melanoma. The cloned cDNA, designated as D‐1, had 1029 bp and showed no significant homology with viral and mammalian sequences stored in GENETYX. cDNA D‐1 hybridized to a 2.0 kb mRNA species from 3 different cell lines of human melanoma, neuroblastoma, erythroleukemia, B lymphoid, and T lymphoid cells, but not from a renal carcinoma cell line, normal peripheral lymphocytes, or normal fibroblasts. The in vivo expression and distribution of mRNA related to cDNA D‐1 has been examined in tissue specimens by in situ hybridization and shown to be rather restricted on melanoma cells. The polypeptide antigen encoded by cDNA D‐1 may be a valuable immunogen for implementing active specific immunotherapy in patients with melanoma.